Cargando…
First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers
BACKGROUND: Inhibition of the epithelial sodium channel (ENaC) represents a mutation-agnostic therapeutic approach to restore airway surface liquid hydration and mucociliary clearance in patients with cystic fibrosis. BI 1265162 is an inhaled ENaC inhibitor with demonstrated preclinical efficacy. ME...
Autores principales: | Mackie, Alison, Rascher, Juliane, Schmid, Marion, Endriss, Verena, Brand, Tobias, Seibold, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861022/ https://www.ncbi.nlm.nih.gov/pubmed/33569494 http://dx.doi.org/10.1183/23120541.00447-2020 |
Ejemplares similares
-
Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis
por: Nickolaus, Peter, et al.
Publicado: (2020) -
An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF(TM) 1
por: Goss, Christopher H., et al.
Publicado: (2020) -
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study
por: Goss, Christopher H., et al.
Publicado: (2022) -
Could a defective epithelial sodium channel lead to bronchiectasis
por: Fajac, Isabelle, et al.
Publicado: (2008) -
Prostasin: An Epithelial Sodium Channel Regulator
por: Aggarwal, Shakti, et al.
Publicado: (2013)